Fresenius Kabi Oncology Limited

Rajesh Khanna

Dhiraj Khattar

Mukti Yadav

Neeraj Kumar

Vijay Kumar Sharma

Ankit Gaur

Krishanu Burman

Sanjay Motwani

Minakshi Garg

Vikas Chandel

Vijay Kumar Kyama

Vikas Bhandari

Sunny Chopra

Vinay Gupta

Rajesh Kini

Abhilasha Yadav

Poonam Singla

The present invention relates to a tablet comprising Afatinib or a pharmaceutically acceptable salt thereof, wherein the tablet is obtained by direct compression. The present invention further relates to a process for manufacturing a tablet of the invention as well as the use of the tablet of the invention.

Pharmaceutical compositions comprising Afatinib

A pharmaceutical composition of Pemetrexed represented by formula (I), which is a liquid ready to use solution formulation or a lyophilized pharmaceutical composition for parenteral administration comprising a pharmaceutically acceptable organic amine, an inert gas and optionally containing at least one or more pharmaceutically acceptable excipients. Also provided are processes for preparation of the ready to use solution formulation or lyophilized pharmaceutical composition of the present invention. 

Pharmaceutical compositions comprising pemetrexed and tromethamine

The present invention relates to a process of preparing a stable pharmaceutical composition of compounds which are susceptible to hydrolysis comprising a. Addition of required quantity of pharmaceutically acceptable lyophilization excipients optionally in Water for Injection in a formulation vessel; b. Addition of organic solvent to form a appropriate proportion of aqueous and organic solvent; c. Maintaining the temperature of the formulation vessel from the range &#x2212;5&#xb1;1&#xb0; C. to &#x2212;5&#xb1;3&#xb0; C.; d. Addition of required quantity of compound susceptible to hydrolysis to form a solution and lyophilizing the solution.

Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis

Described herein are ready to use, non-aqueous pharmaceutical compositions comprising 5-aza-2'-deoxycitidine and at least one aprotic solvent. The pharmaceutical compositions may further comprise at least one protic solvent. Also described are processes for preparing the pharmaceutical compositions and their use for the treatment of patients suffering from myelodysplastic syndromes.

Stable pharmaceutical composition of 5-aza-2'-deoxycitidine

A pharmaceutical composition of Pemetrexed represented by formula (I),  which is a liquid ready to use solution formulation or a lyophilized pharmaceutical composition for parenteral administration comprising a pharmaceutically acceptable organic amine, an inert gas and optionally containing at least one or more pharmaceutically acceptable excipients. Also provided are processes for preparation of the ready to use solution formulation or lyophilized pharmaceutical composition of the present invention.

Growing community of inventors

Gurgaon, India

Rajesh Khanna